Screening (n=1495)

- Not meeting inclusion criteria (n=64)
- Declined to participate (n=255)
- Other reasons (n=94)

Randomized (n=534)

Artesunate-Amodiaquine: ASAQ (n=180)

- Analysed at day 28
- ITT analysis at day 28 (n=180)
- PP analysis at day 28 (n=169)
- Analysed at day 35 (n=160)
- Analysed at day 42 (n=136)

Artemether-Lumefantrine: AL (n=178)

- Analysed at day 28
- ITT analysis at day 28 (n=178)
- PP analysis at day 28 (n=162)
- Analysed at day 35 (n=148)
- Analysed at day 42 (n=134)

Dihydroartemisinin-Piperaquine: DHAPQ (n=176)

- Analysed at day 28
- ITT analysis at day 28 (n=176)
- PP analysis at day 28 (n=162)
- Analysed at day 35 (n=148)
- Analysed at day 42 (n=134)

Follow-up

- Lost to follow-up (n=7)
- Withdraw consent (n=2)
- Protocol violation (n=2)

- Follow up at D 28 (n=169)
- Follow up at D 35 (n=160)
- Follow up at D 42 (n=136)

- Lost to follow-up (n=1)
- Withdraw consent (n=1)
- Protocol violation (n=4)

- Follow up at D 28 (n=172)
- Follow up at D 35 (n=162)
- Follow up at D 42 (n=141)

- Lost to follow-up (n=8)
- Withdraw consent (n=3)
- Protocol violation (n=3)

- Follow up at D 28 (n=162)
- Follow up at D 35 (n=148)
- Follow up at D 42 (n=134)

Analysis

- Analysed at day 28
  - ITT analysis at day 28 (n=180)
  - PP analysis at day 28 (n=169)
  - Analysed at day 35 (n=160)
  - Analysed at day 42 (n=136)

- Analysed at day 28
  - ITT analysis at day 28 (n=178)
  - PP analysis at day 28 (n=162)
  - Analysed at day 35 (n=162)
  - Analysed at day 42 (n=141)

- Analysed at day 28
  - ITT analysis at day 28 (n=176)
  - PP analysis at day 28 (n=162)
  - Analysed at day 35 (n=148)
  - Analysed at day 42 (n=134)